Literature DB >> 18638592

Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention.

Emilia Solinas1, George Dangas, Ajay J Kirtane, Alexandra J Lansky, Theresa Franklin-Bond, Paul Boland, George Syros, Young-Hak Kim, Anuj Gupta, Gary Mintz, Martin Fahy, Michael Collins, Susheel Kodali, Gregg W Stone, Jeffrey W Moses, Martin B Leon, Roxana Mehran.   

Abstract

Patterns of in-stent restenosis (ISR) after drug-eluting stent (DES) implantation and outcomes after treatment have not been studied systematically in all comers. We compared patterns of ISR and outcomes of repeated percutaneous coronary intervention in consecutive patients with DES-ISR. A total of 137 patients with 182 lesions underwent repeated percutaneous coronary intervention for DES-ISR at Columbia University Medical Center from August 2004 to April 2006. DES-ISR was treated with repeated DES placement in 84% of patients and balloon angioplasty in 16%. There was 1 stent thrombosis at 30 days, and at 1 year, major adverse cardiac events occurred in 10% of patients, driven primarily by an 8% rate of target-lesion revascularization. After exclusion of 12 patients with multiple ISR lesions, data were further analyzed from 125 patients with 152 DES-ISR lesions, of which 118 were originally treated with sirolimus-eluting stents and 34 were treated with paclitaxel-eluting stents (PES-ISR). Baseline features were well matched between the 2 groups, except that patients with PES-ISR were older. A focal pattern of ISR was observed in 69.5% of patients overall. However, patients originally treated with a PES had a significantly higher frequency of diffuse-intrastent ISR in comparison with sirolimus-eluting stent ISR (30.3% vs 13.6%, p = 0.03). In conclusion, the pattern of ISR in most DES-ISR in this unselected patient population was focal, with higher rates of diffuse intrastent restenosis seen with PES-ISR. Treatment with either repeated DES implantation or balloon angioplasty for DES-ISR was safe and associated with low overall rates of target-lesion revascularization and major adverse cardiac events at 1 year.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18638592     DOI: 10.1016/j.amjcard.2008.03.060

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

Review 1.  Restenosis after PCI. Part 2: prevention and therapy.

Authors:  J Wouter Jukema; Tarek A N Ahmed; Jeffrey J W Verschuren; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2011-10-11       Impact factor: 32.419

2.  Angiographic patterns of in-stent restenosis classified by computed tomography in patients with drug-eluting stents: correlation with invasive coronary angiography.

Authors:  Jingwei Pan; Zhigang Lu; Jiayin Zhang; Minghua Li; Meng Wei
Journal:  Eur Radiol       Date:  2012-07-08       Impact factor: 5.315

3.  The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis.

Authors:  Ying Xue; Zhi-Wei Feng; Xiao-Ye Li; Zi-Heng Hu; Qing Xu; Zi Wang; Jia-Hui Cheng; Hong-Tao Shi; Qi-Bing Wang; Hong-Yi Wu; Xiang-Qun Xie; Qian-Zhou Lv
Journal:  Acta Pharmacol Sin       Date:  2017-09-21       Impact factor: 6.150

4.  A TEMPOL and rapamycin loaded nanofiber-covered stent favors endothelialization and mitigates neointimal hyperplasia and local inflammation.

Authors:  Rui Wang; Jian Lu; Jiasheng Yin; Han Chen; Hongmei Liu; Fei Xu; Tongtong Zang; Rende Xu; Chenguang Li; Yizhe Wu; Qilin Wu; Xiang Fei; Meifang Zhu; Li Shen; Junbo Ge
Journal:  Bioact Mater       Date:  2022-05-11

Review 5.  Women and ischemic heart disease: evolving knowledge.

Authors:  Leslee J Shaw; Raffaelle Bugiardini; C Noel Bairey Merz
Journal:  J Am Coll Cardiol       Date:  2009-10-20       Impact factor: 24.094

6.  Coronary stent CD31-mimetic coating favours endothelialization and reduces local inflammation and neointimal development in vivo.

Authors:  Sergio Diaz-Rodriguez; Charlotte Rasser; Jules Mesnier; Pascale Chevallier; Romain Gallet; Christine Choqueux; Guillaume Even; Neila Sayah; Frédéric Chaubet; Antonino Nicoletti; Bijan Ghaleh; Laurent J Feldman; Diego Mantovani; Giuseppina Caligiuri
Journal:  Eur Heart J       Date:  2021-05-07       Impact factor: 29.983

7.  Inverse Relationship between Serum VEGF Levels and Late In-Stent Restenosis of Drug-Eluting Stents.

Authors:  Jiasheng Yin; Li Shen; Meng Ji; Yizhe Wu; Sishi Cai; Jiahui Chen; Zhifeng Yao; Junbo Ge
Journal:  Biomed Res Int       Date:  2017-03-08       Impact factor: 3.411

8.  Therapeutic strategy for in-stent restenosis based on the restenosis pattern after drug-eluting stent implantation.

Authors:  Ki-Hun Kim; Doo-Il Kim; Il-Hwan Kim; Jong-Yoon Kim; Yang-Chun Han; Sang-Hoon Seol; Ung Kim; Tae-Hyun Yang; Dae-Kyeong Kim; Dong-Soo Kim; Sang-Hee Lee; Jong-Seon Park; Young-Jo Kim; Dong-Gu Shin; Yoon-Kyung Cho; Chang-Wook Nam; Seung-Ho Hur; Kwon-Bae Kim
Journal:  Korean Circ J       Date:  2009-10-28       Impact factor: 3.243

9.  Mid-Term Follow-Up of Drug-Eluting Stenting for In-Stent Restenosis: Bare-Metal Stents versus Drug-Eluting Stents.

Authors:  Negar Faramarzi; Mojtaba Salarifar; Seyed Ebrahim Kassaian; Ali Mohammad Haji Zeinali; Mohammad Alidoosti; Hamidreza Pourhoseini; Ebrahim Nematipour; Mohammad Reza Mousavi; Hamidreza Goodarzynejad
Journal:  J Tehran Heart Cent       Date:  2013-01-08

10.  Neoatherosclerosis causing edge in-stent restenosis: optical coherence tomography findings.

Authors:  F Alfonso; J Restrepo; J Cuesta; T Bastante; F Rivero; A Benedicto
Journal:  Neth Heart J       Date:  2015-05       Impact factor: 2.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.